Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans1, 2. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing SIV Gag failed to reduce peak or setpoint viral loads following...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Liu, Jinyan, O’Brien, Kara L., Lynch, Diana M., Simmons, Nathaniel L., La Porte, Annalena, Riggs, Ambryice M., Abbink, Peter, Coffey, Rory T., Grandpre, Lauren E., Seaman, Michael S., Landucci, Gary, Forthal, Donald N., Montefiori, David C., Carville, Angela, Mansfield, Keith G., Havenga, Menzo J., Pau, Maria G., Goudsmit, Jaap, Barouch, Dan H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2614452/
https://ncbi.nlm.nih.gov/pubmed/18997770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature07469
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller